a public good project by the
Synthesis
Company
of California

© 2026

Danielle M. Brennan | doi.page

0 works0 citations0 h-index

Danielle M. Brennan

AstraZeneca (United Kingdom)(GB)Cleveland Clinic(US)Center for Clinical Research (United States)(US)

Publications by Year

Research Areas

Lipoproteins and Cardiovascular Health, Antiplatelet Therapy and Cardiovascular Diseases, Acute Myocardial Infarction Research, Coronary Interventions and Diagnostics, Cardiac Imaging and Diagnostics

Most-Cited Works

→ Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events(2006)2,814 cited
→ Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients(2016)1,112 cited
→ Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients(2023)800 cited
→ Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance(2016)506 cited
→ Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome(2014)333 cited
→ Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial(2003)266 cited

→ Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease(2010)

231 cited

→ Diminished Global Arginine Bioavailability and Increased Arginine Catabolism as Metabolic Profile of Increased Cardiovascular Risk(2009)229 cited

→ Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts(2002)215 cited

→ Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis(2008)209 cited